Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("P
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-06-30 4:30 PM EDT | Theralase Technologies Inc.
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submissi
Biotechnologies, Soins de santé et hôpitaux
2026-06-30 8:30 AM EDT | Envoy Medical, Inc.
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall survival as approval endpoint Biomarker data submitted to FDA BEST program as surrogate clinical efficacy data Synthetic historical control arm OST-400 recruitment potentially adds comparator for BLA submission under the Accelerated Approva
2026-06-30 7:40 AM EDT | OS Therapies
Illumisoft and Capgemini Collaborate to Advance Human-Safe Far UVC Platform for Airborne Pathogen Risk Reduction in High-Occupancy Indoor Environments
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") is developing its SaniLux 216 nanometre far ultraviolet C ("far UVC") disinfection platform to enable the safe mitigation of airborne pathogen risk in high-occupancy indoor environments where people live, work, learn, travel, and gather. Today, the Company announced that it is taking steps to accelerate the platform's development. To support the path to m
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-06-30 7:00 AM EDT | Illumisoft Lighting Corporation
TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the la
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-06-30 3:05 AM EDT | TempraMed Technologies Ltd.
PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy
Saskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporati
Biotechnologies, Pharmaceutique, Commerce de détail
2026-06-29 7:15 AM EDT | PharmaCorp RX Inc.
American Aires Announces Letter of Intent for Proposed Sale of Assets
Toronto, Ontario--(Newsfile Corp. - June 29, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that it has entered into a non-binding letter of intent dated June 25, 2026 (the "Letter Agreement") with an arm's-length third party purchaser (the "Purchaser") in respect of a proposed transaction pursuant to which the Purchaser would acquire certain specified assets and related rights of the Company (the "Transaction"). Under the
2026-06-29 7:00 AM EDT | American Aires Inc.
American Aires Announces Settlement Agreement with Former Officer and Director and Assignment of Patent Rights to the Company
Toronto, Ontario--(Newsfile Corp. - June 29, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that it has entered into a settlement agreement and mutual release (the "Settlement Agreement") with its former officer and director, Dimitry Serov, and Serov Holdings Inc., pursuant to which the parties have agreed to resolve all outstanding disputes between them, including the litigation commenced by the Company in the Ontario Superior Court of Justi
2026-06-29 6:00 AM EDT | American Aires Inc.
Telo Genomics Announces Termination of Investor Relations Agreement
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially u
2026-06-26 8:58 PM EDT | Telo Genomics Corp.
MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2026 annual meeting of shareholders (the "Meeting") held on June 25, 2026. At the Meeting, all director nominees listed in the Company's management information circular dated May 28, 2026, were elected by shareholders as directors of the Company on a vote held by ballot.
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-06-26 5:00 PM EDT | MustGrow Biologics Corp.
TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI") dated June 16, 2026 with Rawafed Health International Company ("Rawafed"), a leading healthcare distribution company with broad reach across pharmacy networks a
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-06-26 4:10 PM EDT | TempraMed Technologies Ltd.
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at
Biotechnologies, Pharmaceutique, Santé
2026-06-26 8:47 AM EDT | Hemostemix Inc.
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs per year diagnosed with osteosarcoma Company expects to submit U.S. Department of Agriculture meeting request to gain alignment on regulatory path towards conditional approval in the third quarter of 2026 OS Therapies reiterates plan to distribute OS Animal Health shares to shareholders OS Animal
2026-06-26 7:40 AM EDT | OS Therapies
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-06-25 9:12 PM EDT | Resverlogix Corp.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its com
Biotechnologies, Soins de santé et hôpitaux
2026-06-25 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Illumisoft Appoints Former White House Chief Healthcare Economist Jonathan Ketcham as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") today announced the appointment of Jonathan Ketcham as a strategic advisor to the Company. Dr. Ketcham brings deep expertise in healthcare economics, public policy, reimbursement, procurement, and technology adoption. His guidance is expected to benefit Illumisoft greatly as it advances its ultraviolet germicidal technology platform toward commercializati
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-06-25 7:00 AM EDT | Illumisoft Lighting Corporation
Dr. Christina Rahm and DRC Ventures Accept Prestigious Gold Stevie(R) Award for Patent-Driven Manufacturing Innovation
New York, New York--(Newsfile Corp. - June 24, 2026) - Dr. Christina Rahm, founder and CEO of DRC Ventures, was honored with a Gold Stevie® Award at the 2026 American Business Awards® ceremony in New York City for her groundbreaking work in developing the patent-driven manufacturing infrastructure
Biotechnologies, Aliments / boissons, Santé
2026-06-24 1:20 PM EDT | DRC Ventures